Artificial Intelligence to Predict the BRAF V595E Mutation in Canine Urinary Bladder Urothelial Carcinomas
Source check: Source checked. Not independent scientific confirmation.
Finding: U-Net analysis of H&E slides predicts PCR-confirmed canine BRAF V595E mutation in a held-out set of 84 cases; sensitivity/specificity are modest and materially depend on tissue quality, so the finding is a bounded veterinary diagnostic proof of concept. PCR is a reference standard in a case-held-out validation set; performance is limited (57/96 agreement; 58% sensitivity, 63% specificity) and quality-dependent, with no external site validation.
Technology: Visiopharm decision-forest tissue segmentation and U-Net tumor segmentation/mutation prediction operate on H&E whole-slide images, trained against ddPCR and compared with PCR in held-out cases.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Visiopharm decision-forest tissue segmentation and U-Net tumor segmentation/mutation prediction operate on H&E whole-slide images, trained against ddPCR and compared with PCR in held-out cases.
- Test and result
- The result is prediction of a molecular tumor mutation from routine histology images, a specific diagnostic application; BRAF mutation itself was known before this paper.
- Limitation / still unknown
- PCR is a reference standard in a case-held-out validation set; performance is limited (57/96 agreement; 58% sensitivity, 63% specificity) and quality-dependent, with no external site validation. The source does not establish benefits beyond the reported evaluation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC10416820/unicode · https://doi.org/10.3390/ani13152404
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.